ArticleJournal of gastrointestinal cancer2008
Evaluation of CD44 and CD44v6 in colorectal carcinoma patients: soluble forms in relation to tumor tissue expression and metastasis.
Article in Journal of gastrointestinal cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- The Prognostic and Clinical Value of CD44 in Colorectal Cancer: A Meta-Analysis.Frontiers in oncology · 2019Pooled it
- Genetic attenuation of ALDH1A1 increases metastatic potential and aggressiveness in colorectal cancer.Molecular oncology · 2026Article
- Digging into the Solubility Factor in Cancer Diagnosis: A Case of Soluble CD44 Protein.Biosensors · 2025Review
- Comprehensive Analysis of Ferroptosis- and Immune-Related Signatures to Improve the Prognosis and Diagnosis of Kidney Renal Clear Cell Carcinoma.Frontiers in immunology · 2022Article
- Gene expression and DNA methylation analyses suggest that two immune related genes are prognostic factors of colorectal cancer.BMC medical genomics · 2021Article
- Baseline CD44v6-positive circulating tumor cells to predict first-line treatment failure in patients with metastatic colorectal cancer.Oncotarget · 2020Article
- CD44 splice variant (CD44v3) promotes progression of urothelial carcinoma of bladder through Akt/ERK/STAT3 pathways: novel therapeutic approach.Journal of cancer research and clinical oncology · 2019Article
- Correlation analysis of expression and prognosis of TTF-1 and CD44v6 in undifferentiated lung carcinoma.Oncology letters · 2019Article
- The loss of CD44 and HSP70 overexpression is related to aggressive clinicopathologic factors in prostate cancer.International journal of clinical and experimental pathology · 2018Article
- Hyaluronic acid-coated chitosan nanoparticles induce ROS-mediated tumor cell apoptosis and enhance antitumor efficiency by targeted drug delivery via CD44.Journal of nanobiotechnology · 2017Article
- CD44v6 down-regulation is an independent prognostic factor for poor outcome of colorectal carcinoma.International journal of clinical and experimental pathology · 2015Article
- CD44v6 expression in patients with stage II or stage III sporadic colorectal cancer is superior to CD44 expression for predicting progression.International journal of clinical and experimental pathology · 2015Article
- Effects of different sequences of pulmonary artery and vein ligations during pulmonary lobectomy on blood micrometastasis of non-small cell lung cancer.Oncology letters · 2013Article
- Pilot study: alteration of deleted in liver cancer1 and phosphorylated focal adhesion kinase Y397 cytoplasmic expression and the prognostic value in advanced epithelial ovarian carcinoma.International journal of molecular sciences · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIt has been shown that CD44 may be associated with poor prognosis in various human malignancies. This study was designed to investigate and compare the prognostic relevance and clinical value of soluble forms of CD44 and its variant v6 (CD44v6) and their tissue expression in colorectal carcinoma. MATERIALS AND
methodsSerum levels of pre- and postoperative CD44 and CD44v6 molecules were evaluated in 37 colorectal cancer patients and compared to healthy individuals. RESULTS AND DISCUSSION: The serum levels of soluble CD44 and CD44v6 showed no significant decrease after surgical resection of the tumor (p = 0.5). Both CD44 and CD44v6 serum levels either before or after surgery were significantly higher in patients than in normal individuals (p < 0.001). The serum level of CD44v6 molecule was higher in patients with lymph node metastasis than other patients (p = 0.05) implying the role of this molecule in tumor progression. Immunohistochemical staining showed expression of CD44 in 14.3% and CD44v6 in 42.9% of the tumor samples. The expression of CD44v6 was associated with metastatic involvement of lymph nodes (p = 0.03). CD44v6 expression was positively correlated with its level in the serum of patients (p = 0.04).
conclusionsResults of this study showed that CD44v6 expression level either in the soluble form or in the cell membrane is associated with tumor metastasis indicating the importance of this molecule in progression of colorectal carcinoma. The serum levels of soluble CD44 as well as CD44v6 might be useful markers for tumor screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.